Literature DB >> 21664761

Depression in relation to anxiety, obsessionality and phobia among neurosurgical patients with a primary brain tumor: a 1-year follow-up study.

Arja Mainio1, Helinä Hakko, Asko Niemelä, John Koivukangas, Pirkko Räsänen.   

Abstract

Depression is found to be present in up to 44% of brain tumor patients during their illness process. Anxiety as a comorbid psychiatric disorder with depression has formerly been studied, but phobia or obsessive-compulsive symptoms among brain tumor patients have not yet been noticed. By using a clinical prospective database of primary brain tumor patients (n=77) we studied the level of depression, anxiety, obsessionality (traits and symptoms) and phobic anxiety symptoms. Psychiatric symptoms were assessed before tumor operation as well as at three months and at one year after operation. The presence of comorbid anxiety, obsessionality and phobic anxiety symptoms was assessed before operation and at follow-ups in depressed and non-depressed patients, separately. Before tumor operation 16% of the patients had depression according to Beck Depression Inventory (BDI), while 10% had depression at three months and 15% at one year after operation. The depressed patients had statistically significantly higher anxiety scores and phobic scores at all three measurement points compared to corresponding scores among non-depressed brain tumor patients. The mean obsessionality scores among depressed brain tumor patients were significantly higher when measured before operation and at one year after the operation compared to non-depressed patients. To our knowledge, this is the first study so far in which comorbidity of psychiatric symptoms has been shown among depressive brain tumor patients. Concurrent comorbid conditions have been shown to be associated with increased severity, morbidity and chronicity of depression. It is recommended that treatment of depressive patients complicated with comorbid psychiatric disorders be planned by psychiatric units.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21664761     DOI: 10.1016/j.clineuro.2011.05.006

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  6 in total

1.  Evaluating patients for psychosocial distress and supportive care needs based on health-related quality of life in primary brain tumors: a prospective multicenter analysis of patients with gliomas in an outpatient setting.

Authors:  Anne-Katrin Hickmann; Marlene Hechtner; Minou Nadji-Ohl; Mareile Janko; Ann Katrin Reuter; Karoline Kohlmann; Markus Haug; Sonja Grüninger; Monika Deininger; Oliver Ganslandt; Jochem König; Christian Rainer Wirtz; Jan Coburger; Mirjam Renovanz
Journal:  J Neurooncol       Date:  2016-09-16       Impact factor: 4.130

Review 2.  Psychiatric aspects of brain tumors: A review.

Authors:  Subramoniam Madhusoodanan; Mark Bryan Ting; Tara Farah; Umran Ugur
Journal:  World J Psychiatry       Date:  2015-09-22

Review 3.  Depression screening in patients with brain tumors: a review.

Authors:  Aiste Pranckeviciene; Adomas Bunevicius
Journal:  CNS Oncol       Date:  2015

4.  Effect of low-dose ketamine on PerioperAtive depreSsive Symptoms in patients undergoing Intracranial tumOr resectioN (PASSION): study protocol for a randomized controlled trial.

Authors:  Yang Zhou; Yuming Peng; Jinghan Fang; Wanchen Sun; Guofu Zhang; Long Zhen; Gang Wang; Ruquan Han
Journal:  Trials       Date:  2018-08-29       Impact factor: 2.279

5.  Effect of esketamine on perioperative depressive symptoms in major surgery patients (PASSION II): study protocol for a randomised controlled trial.

Authors:  Yang Zhou; Bo Ma; Wanchen Sun; Juan Wang; Yuxuan Fu; Anxin Wang; Gang Wang; Ruquan Han
Journal:  BMJ Open       Date:  2022-04-26       Impact factor: 2.692

6.  Psychotropic and anti-epileptic drug use, before and after surgery, among patients with low-grade glioma: a nationwide matched cohort study.

Authors:  Isabelle Rydén; Erik Thurin; Louise Carstam; Anja Smits; Sasha Gulati; Roger Henriksson; Øyvind Salvesen; Asgeir Store Jakola
Journal:  BMC Cancer       Date:  2021-03-08       Impact factor: 4.638

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.